Today in Medmultilingua
Somewhere between millions of potential molecules and the urgency of waiting patients, artificial intelligence has found its most promising niche: the laboratory. A recent announcement from Insilico Medicine reveals how a generative AI platform designed the first preclinical drug candidate in the United Arab Emirates—a PRMT5 enzyme inhibitor—in just six months, using approximately 90 molecules screened. This achievement would have taken years using traditional methods. [Read more]





